Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC] Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Laurie, Scott A
  • Arnold, Andrew
  • Shepherd, Frances A
  • Dediu, Mircea
  • Ciuleanu, Tudor
  • Fenton, David
  • Zukin, Mauro
  • Goss, Glenwood
  • Ding, Keyue
  • Seymour, Lesley

publication date

  • September 1, 2009